Fibrosis is the strongest predictor of severe liver-related consequences and its progression can be rapid and unpredictable1-3

Mortality Risk Liver Dysfunction Undiagnosed Disease

Starting at F2, the risk of mortality increases substantially with each stage of fibrosis1

Bar chart conveying the increased mortality risk per increasing stage of fibrosis.

Dysfunction of critical processes in the liver fuels fibrosis progression4

MASH is a complex, heterogeneous disease in which impaired liver processes drive fibrosis progression, worsening the liver's ability to perform its natural functions, including4,5:

  • Lipid metabolism (including cholesterol, triglycerides, and lipoproteins)6

  • Nutrient and bile processing6

  • Detoxification6

  • Regulation of blood sugar levels6

  • Immune function6

  • Hormone regulation6

Learn about a management option that targets a pathway responsible for liver dysfunction and fibrosis progression

Discover a management option

With advanced liver disease often being unrecognized, early assessment
of fibrosis is critical to enable timely intervention before cirrhosis7,8

According to claims data from a retrospective real-world cohort study of 19,419 patients with MASH, 22% (4235) were subsequently identified as having features of end-stage liver disease (cirrhosis, decompensated cirrhosis, liver transplant, or liver cancer) over an average of ~3 years from index date.7*†

~50%

were recognized as having features of end-stage liver disease within 1 year7‡

~80%

were identified with features of decompensated cirrhosis within 3 years7‡

The unpredictability and risks of fibrosis progression
make timely intervention critical2

Defuse the threat

*Based on US health insurance claims data from large commercial and Medicare Advantage health plans. Patients were identified based on first captured MASH diagnosis within a 6-month period and may not necessarily reflect first-ever diagnosis (epidemiological data).7 

†Index date was defined as 30 days following first MASH diagnosis code to capture for delays in cirrhosis coding at baseline. MASH diagnosis was defined as ≥1 inpatient or ≥2 outpatient claims for ICD-10-CM K75.81 [MASH] after applying an exclusion criteria, between 2015 and 2022.7

‡Percentage of the 4235 patients with progression to end-stage liver disease.7

MASH=metabolic dysfunction-associated steatohepatitis.

References: 1. Dulai PS et al. Hepatology. 2017;65(5):1557-1565. 2. Rinella ME et al. Hepatology. 2023;77(5):1797-1835. 3. Singh S et al. Clin Gastroenterol Hepatol. 2015;13(4):643-654. 4. Karim G, Bansal MB. touchREV Endocrinol. 2023;19(1):60-70. 5. Schwabe RF et al. Gastroenterology. 2020;158(7):1913-1928. 6. Trefts E et al. Curr Biol. 2017;27(21):R1147-R1151. 7. Fishman JC et al. J Manag Care Spec Pharm. 2024;30(9)(article and suppl):929-941. 8. Kanwal F et al. Gastroenterology. 2021;161(5):1657-1669.